Reviewing Allena Pharmaceuticals Inc. (ALNA)’s and G1 Therapeutics Inc. (NASDAQ:GTHX)’s results

This is a contrast between Allena Pharmaceuticals Inc. (NASDAQ:ALNA) and G1 Therapeutics Inc. (NASDAQ:GTHX) based on their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allena Pharmaceuticals Inc. N/A 0.00 39.19M -1.89 0.00
G1 Therapeutics Inc. N/A 0.00 88.83M -2.57 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Allena Pharmaceuticals Inc. and G1 Therapeutics Inc.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Allena Pharmaceuticals Inc. 0.00% -73.3% -57.3%
G1 Therapeutics Inc. 0.00% -28.3% -27.2%


Allena Pharmaceuticals Inc.’s Current Ratio is 7.8 while its Quick Ratio is 7.8. On the competitive side is, G1 Therapeutics Inc. which has a 30.2 Current Ratio and a 30.2 Quick Ratio. G1 Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Allena Pharmaceuticals Inc.

Institutional and Insider Ownership

Institutional investors owned 88.3% of Allena Pharmaceuticals Inc. shares and 86.5% of G1 Therapeutics Inc. shares. Insiders owned 8.27% of Allena Pharmaceuticals Inc. shares. Competitively, G1 Therapeutics Inc. has 0.5% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Allena Pharmaceuticals Inc. -5.13% -5.91% -10.33% -29.35% -64.63% 5.14%
G1 Therapeutics Inc. 13.68% 35.75% 12.76% -47.95% -49.4% 24.13%

For the past year Allena Pharmaceuticals Inc. was less bullish than G1 Therapeutics Inc.


On 4 of the 6 factors G1 Therapeutics Inc. beats Allena Pharmaceuticals Inc.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The companyÂ’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.